FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2318526554> ?p ?o ?g. }

• W2318526554 abstract "Background The recently published EULAR treatment guideline recommended treatment for DMARD naive patients is Methotrexate (MTX) with(out) glucocorticoids (GCs). Combination therapy with classical DMARDs however is not recommended, because well proven evidence of superior efficacy is suggested to be lacking. Furthermore possible drug toxicities might influence the physician’s choice of induction therapy. Objectives To compare the 3 month clinical efficacy of: (1) combination DMARD vs. MTX mono-therapy and (2) oral GCs bridging therapy vs. 1 dose of intramuscular (im) GCs in patients with early RA. Methods For this study data are used of a currently ongoing single-blinded randomized clinical trial in patients ≥18 years with recent-onset arthritis (tREACH). We included patients who had a high probability (>70%) according to their likelihood of progressing to persistent arthritis based of the prediction model of Visser. The Visser algorithm and 2010 criteria for RA have similar discriminative abilities to identify patients at risk of persistent arthritis at 1 year. Patients were randomized into 3 induction therapy strategies: (A) Combination therapy (MTX 25 mg/wk + SASP 2 gr./day + HCQ 400 mg/day) with GCs im (Depomedrol 120mg), (B) Combination therapy with an oral GCs tapering scheme (starting dose 15 mg) and (C) MTX with oral GCs similar to B. In case of “treatment failure”, defined as DAS>2.4, medication is intensified to MTX with a biological. Disease activity, functional ability, and adverse events were assessed. Results A total of 281 patients were randomly assigned to [A] (n=91), [B] (n=93) or [C] (n=97). Disease activity, after 3 months, was 0.39 (0.67–0.11, 95% CI) lower in patients with initial combination therapy compared to MTX mono-therapy. Difference in disease activity between the different GCs bridging therapies was 0.03 (–0.24–0.31, 95% CI). After three months 50% less biologicals were prescribed in the combination therapy groups. Functional ability (respectively 0.53 (0.40–0.66) [A] vs 0.53 (0.40–0.65) [B] vs 0.69 (0.55–0.84) [C]) and medication adjustments due to adverse events (resp. 22% [A] vs 20% [B] vs 16% [C]) did not differ between groups. Conclusions In patients with >70% chance of developing a RA a combination of DMARDs is superior to MTX mono-therapy in achieving low disease activity after three months, unbiased for GCs. Consequently 50% less biologicals were prescribed in the combination therapy groups. Furthermore intramuscular and oral GCs are equally effective as bridging therapy and can both be used. Funding Unrestricted grant from Pfizer bv. [0881-102217] Disclosure of Interest None Declared" @default.
• W2318526554 created "2016-06-24" @default.
• W2318526554 creator A5013634730 @default.
• W2318526554 creator A5017391629 @default.
• W2318526554 creator A5033379770 @default.
• W2318526554 creator A5040025839 @default.
• W2318526554 creator A5045760753 @default.
• W2318526554 creator A5053658842 @default.
• W2318526554 creator A5053775888 @default.
• W2318526554 creator A5060529637 @default.
• W2318526554 creator A5064933388 @default.
• W2318526554 creator A5069122327 @default.
• W2318526554 creator A5075040024 @default.
• W2318526554 creator A5075713646 @default.
• W2318526554 date "2013-06-01" @default.
• W2318526554 modified "2023-09-26" @default.
• W2318526554 title "SAT0111 Induction therapy with a combination of dmards is superior to methotrexate mono-therapy, unbiased for corticosteroids" @default.
• W2318526554 doi "https://doi.org/10.1136/annrheumdis-2012-eular.3058" @default.
• W2318526554 hasPublicationYear "2013" @default.
• W2318526554 type Work @default.
• W2318526554 sameAs 2318526554 @default.
• W2318526554 citedByCount "2" @default.
• W2318526554 countsByYear W23185265542012 @default.
• W2318526554 countsByYear W23185265542013 @default.
• W2318526554 crossrefType "journal-article" @default.
• W2318526554 hasAuthorship W2318526554A5013634730 @default.
• W2318526554 hasAuthorship W2318526554A5017391629 @default.
• W2318526554 hasAuthorship W2318526554A5033379770 @default.
• W2318526554 hasAuthorship W2318526554A5040025839 @default.
• W2318526554 hasAuthorship W2318526554A5045760753 @default.
• W2318526554 hasAuthorship W2318526554A5053658842 @default.
• W2318526554 hasAuthorship W2318526554A5053775888 @default.
• W2318526554 hasAuthorship W2318526554A5060529637 @default.
• W2318526554 hasAuthorship W2318526554A5064933388 @default.
• W2318526554 hasAuthorship W2318526554A5069122327 @default.
• W2318526554 hasAuthorship W2318526554A5075040024 @default.
• W2318526554 hasAuthorship W2318526554A5075713646 @default.
• W2318526554 hasConcept C126322002 @default.
• W2318526554 hasConcept C168563851 @default.
• W2318526554 hasConcept C197934379 @default.
• W2318526554 hasConcept C2776999253 @default.
• W2318526554 hasConcept C2777077863 @default.
• W2318526554 hasConcept C2777575956 @default.
• W2318526554 hasConcept C2781059491 @default.
• W2318526554 hasConcept C500440147 @default.
• W2318526554 hasConcept C535046627 @default.
• W2318526554 hasConcept C71924100 @default.
• W2318526554 hasConceptScore W2318526554C126322002 @default.
• W2318526554 hasConceptScore W2318526554C168563851 @default.
• W2318526554 hasConceptScore W2318526554C197934379 @default.
• W2318526554 hasConceptScore W2318526554C2776999253 @default.
• W2318526554 hasConceptScore W2318526554C2777077863 @default.
• W2318526554 hasConceptScore W2318526554C2777575956 @default.
• W2318526554 hasConceptScore W2318526554C2781059491 @default.
• W2318526554 hasConceptScore W2318526554C500440147 @default.
• W2318526554 hasConceptScore W2318526554C535046627 @default.
• W2318526554 hasConceptScore W2318526554C71924100 @default.
• W2318526554 hasLocation W23185265541 @default.
• W2318526554 hasOpenAccess W2318526554 @default.
• W2318526554 hasPrimaryLocation W23185265541 @default.
• W2318526554 isParatext "false" @default.
• W2318526554 isRetracted "false" @default.
• W2318526554 magId "2318526554" @default.
• W2318526554 workType "article" @default.